or Try an Advanced Search...

    Technical Analysis for ROIV - Roivant Sciences Ltd.

    Grade Last Price % Change Price Change
    D 11.29 1.12% 0.13
    ROIV closed down 0.36 percent on Monday, November 18, 2024, on 66 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical ROIV trend table...
    Date Alert Name Type % Chg
    Fell Below 200 DMA Bearish 1.12%
    NR7 Range Contraction 1.12%
    Lower Bollinger Band Walk Weakness 1.12%
    Stochastic Reached Oversold Weakness 1.12%
    Below Lower BB Weakness 1.12%
    Down 3 Days in a Row Weakness 1.12%
    Oversold Stochastic Weakness 1.12%
    MACD Bearish Centerline Cross Bearish 0.76%
    MACD Bearish Signal Line Cross Bearish 0.76%
    Expansion Pivot Sell Setup Bearish Swing Setup 0.76%
    Older End-of-Day Signals for ROIV ...

       Recent Intraday Alerts

    Alert Time
    Up 1% about 3 hours ago
    60 Minute Opening Range Breakout about 3 hours ago
    Rose Above Previous Day's High about 4 hours ago
    Rose Above Lower Bollinger Band about 4 hours ago
    200 DMA Resistance about 4 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ROIV Chart by TradingView
    Basic chart:

    Profile

    Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Immunology Autoimmune Disease Antibodies Inflammation Monoclonal Antibodies Psoriasis Ulcerative Colitis Abdominal Pain Atopic Dermatitis Crohn's Disease Treatment Of Psoriasis

    Is ROIV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 19 Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution
    Nov 12 Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
    Nov 12 Roivant Sciences Ltd. 2024 Q2 - Results - Earnings Call Presentation
    Nov 12 Roivant Sciences GAAP EPS of -$0.25, revenue of $4.48M
    Nov 12 Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
    Nov 12 Earnings Scheduled For November 12, 2024
    Oct 29 Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
    Oct 28 Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    Oct 22 Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
    Sep 19 Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
    See more ROIV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.055
    52 Week Low 8.5621
    Average Volume 6,334,780
    200-Day Moving Average 11.20
    50-Day Moving Average 11.72
    20-Day Moving Average 11.67
    10-Day Moving Average 11.64
    Average True Range 0.31
    RSI (14) 38.65
    ADX 12.7
    +DI 16.39
    -DI 27.12
    Chandelier Exit (Long, 3 ATRs) 11.20
    Chandelier Exit (Short, 3 ATRs) 11.96
    Upper Bollinger Bands 12.07
    Lower Bollinger Band 11.27
    Percent B (%b) -0.14
    BandWidth 6.87
    MACD Line -0.07
    MACD Signal Line -0.01
    MACD Histogram -0.0564
    Fundamentals Value
    Market Cap 8.97 Billion
    Num Shares 804 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -7.59
    Price-to-Sales 84.25
    Price-to-Book 8.96
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.44
    Resistance 3 (R3) 11.43 11.33 11.39
    Resistance 2 (R2) 11.33 11.26 11.33 11.38
    Resistance 1 (R1) 11.25 11.22 11.20 11.25 11.36
    Pivot Point 11.15 11.15 11.12 11.15 11.15
    Support 1 (S1) 11.06 11.07 11.01 11.07 10.96
    Support 2 (S2) 10.96 11.03 10.96 10.94
    Support 3 (S3) 10.88 10.96 10.93
    Support 4 (S4) 10.88